Antibiotics Should Be One Step On FDA’s “Critical Path,” Lilly VP Cassell Says

The therapeutic category is ideal for FDA’s drug development initiative because antibiotics do not pose antitrust concerns and NIH has allocated $1.7 bil. for research in the area of anti-infectives, the Lilly exec asserts.